Medical Device

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Member states reported 309 significant cybersecurity incidents affecting the healthcare sector in 2023 – more than in any other critical sector.

In an exclusive interview with Generics Bulletin, Aspargo Labs CEO Michael Demurjian discusses the importance of reformulated liquid oral suspension drugs, while outlining plans to launch a smart device that connects patients and doctors.

Royal Philips is at the forefront of the driving environmental sustainability along the Scope 1-2-3 chain. The company hosted a round table in Amsterdam to hear experiences from providers.

“What a mess! … The MDR is a complete disaster,” critics tell European Commission.

ZS principal Brian Chapman tells In Vivo what is troubling the global medtech industry at the turn of 2025, and takes the opportunity to chide the EU for its persistent fixation on taking on the “problem that did not need to be solved.”

The fight between Teva and Amneal over the ProAir HFA inhaler has reached another milestone, with the appellate court affirming the previous ruling to delist five patents from the FDA’s Orange Book. However, Teva might not be backing down.

With so many discussions around future change now in the medtech regulatory melting pot as 2025 kicks off, it is unsurprising to see an intense calendar of EU meetings ahead. But which topics deserve the most focus?

Medtech Insight spoke to eight well-known EU regulatory experts to find out what developments they expect to see, what they fear and their wish list for 2025.

Medtechs will be indirectly affected by a new law in Switzerland that unifies the amount of funding allocated to inpatient and ambulatory care.